These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35058123)

  • 1. Heart rate variability and sympathetic skin response for the assessment of autonomic dysfunction in leucine-rich repeat kinase 2 associated Parkinson's disease.
    Nasri A; Kacem I; Farhat N; Gharbi A; Sakka S; Souissi A; Zidi S; Damak M; Bendjebara M; Gargouri A; Mhiri C; Gouider R
    Neurophysiol Clin; 2022 Feb; 52(1):81-93. PubMed ID: 35058123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Carricarte Naranjo C; Marras C; Visanji NP; Cornforth DJ; Sanchez-Rodriguez L; Schüle B; Goldman SM; Estévez M; Stein PK; Lang AE; Jelinek HF; Machado A
    Clin Auton Res; 2019 Dec; 29(6):603-614. PubMed ID: 31444591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers.
    Tijero B; Gómez Esteban JC; Somme J; Llorens V; Lezcano E; Martinez A; Rodríguez T; Berganzo K; Zarranz JJ
    Parkinsonism Relat Disord; 2013 Oct; 19(10):906-9. PubMed ID: 23764467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Visanji NP; Bhudhikanok GS; Mestre TA; Ghate T; Udupa K; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kim S; Azhu Valappil R; Kausar F; Rogaeva E; William Langston J; Tanner CM; Schüle B; Lang AE; Goldman SM; Marras C
    Mov Disord; 2017 Apr; 32(4):610-614. PubMed ID: 28071824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
    Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease.
    Cui SS; Fu R; Du JJ; Lin YQ; Huang P; Gao C; Zhou HY; Chen SD
    BMC Neurosci; 2021 Mar; 22(1):22. PubMed ID: 33771108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease.
    Oka H; Toyoda C; Yogo M; Mochio S
    J Neurol; 2010 Jun; 257(6):969-76. PubMed ID: 20119648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
    Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
    Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
    Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.